

Markus G Manz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4634535/publications.pdf>

Version: 2024-02-01

188
papers

17,903
citations

28274

55
h-index

13771

129
g-index

201
all docs

201
docs citations

201
times ranked

22297
citing authors

#	ARTICLE	IF	CITATIONS
1	Asymmetric organelle inheritance predicts human blood stem cell fate. <i>Blood</i> , 2022, 139, 2011-2023.	1.4	32
2	IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. <i>Blood</i> , 2022, 139, 44-58.	1.4	51
3	<i>p53</i> mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. <i>Blood Advances</i> , 2022, 6, 3201-3206.	5.2	8
4	Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells. <i>Blood Advances</i> , 2022, , .	5.2	2
5	Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 214.e1-214.e11.	1.2	32
6	A microbiome-macrophage-iron axis guides stressed hematopoietic stem cell fate. <i>Cell Stem Cell</i> , 2022, 29, 177-179.	11.1	2
7	Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years. <i>Annals of Hematology</i> , 2022, 101, 1097-1106.	1.8	0
8	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. <i>Cancer Medicine</i> , 2022, 11, 630-640.	2.8	3
9	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	26
10	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2022, , .	2.8	0
11	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	3.7	7
12	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	5.2	33
13	Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera. <i>Blood Cancer Journal</i> , 2021, 11, 31.	6.2	5
14	Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. <i>Experimental Hematology</i> , 2021, 95, 31-45.	0.4	15
15	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.	1.8	5
16	Disruption of CSF-1R signaling inhibits growth of AML with inv(16). <i>Blood Advances</i> , 2021, 5, 1273-1277.	5.2	7
17	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. <i>Cancer Cell</i> , 2021, 39, 288-293.	16.8	71
18	Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications. <i>Nature Chemistry</i> , 2021, 13, 540-548.	13.6	42

#	ARTICLE	IF	CITATIONS
19	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. <i>Nature Medicine</i> , 2021, 27, 851-861.	30.7	38
20	Cytokine combinations for human blood stem cell expansion induce cell-type-specific and cytokine-specific signaling dynamics. <i>Blood</i> , 2021, 138, 847-857.	1.4	21
21	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	7.7	34
22	Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	113
23	Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. <i>European Journal of Haematology</i> , 2021, 107, 343-353.	2.2	5
24	Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. <i>British Journal of Haematology</i> , 2021, 194, 931-934.	2.5	11
25	SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues. <i>Leukemia Research</i> , 2021, 107, 106608.	0.8	6
26	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021, 29, 1573-1588.e7.	11.0	71
27	CXCL12-abundant reticular cells are the major source of IL-6 upon LPS stimulation and thereby regulate hematopoiesis. <i>Blood Advances</i> , 2021, 5, 5002-5015.	5.2	9
28	PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, ii2-ii2.	1.2	0
29	Clonal hematopoiesis in hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2021, 28, 94-100.	2.5	7
30	Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, , .	2.5	1
31	Chronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitness. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
32	Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15799-15809.	6.4	8
33	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6436.	12.8	45
34	A Bispecific Antibody Targeting CD117 and CD3 Enables T Cell Mediated Killing of CD117-Expressing Healthy and Malignant Hematopoietic Cells. <i>Blood</i> , 2021, 138, 2354-2354.	1.4	1
35	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021, 12, 6703.	12.8	36
36	Efficient Human Acute Myeloid Leukemia Targeting By Universal Chimeric Antigen Receptor T-Cells Via Combinatorial Use of Linkers. <i>Blood</i> , 2021, 138, 2781-2781.	1.4	2

#	ARTICLE	IF	CITATIONS
37	IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi101-vi101.	1.2	0
38	Clonal Expansion of <i>Tet2</i> +/- hematopoiesis Is Driven By Inflamm-Ageing Associated IL-1 Increase in Mice. <i>Blood</i> , 2021, 138, 1086-1086.	1.4	0
39	Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells. <i>Blood</i> , 2021, 138, 2808-2808.	1.4	1
40	CD117 As an Immunotherapeutic Target in Advanced Forms of Mastocytosis. <i>Blood</i> , 2021, 138, 2538-2538.	1.4	0
41	Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 3894-3894.	1.4	0
42	Preclinical Assessment of CDR101 - a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy. <i>Blood</i> , 2021, 138, 1583-1583.	1.4	6
43	Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 581-592.	2.0	7
44	iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. <i>Stem Cell Reports</i> , 2020, 14, 49-59.	4.8	57
45	BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. <i>Blood Advances</i> , 2020, 4, 4912-4917.	5.2	6
46	A pilot clinical phase II trial MemSID: Acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment. <i>EJHaem</i> , 2020, 1, 23-34.	1.0	9
47	The Innate Immune Response to Infection Induces Erythropoietin-Dependent Replenishment of the Dendritic Cell Compartment. <i>Frontiers in Immunology</i> , 2020, 11, 1627.	4.8	5
48	Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells. <i>Cell Reports</i> , 2020, 32, 108093.	6.4	54
49	MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease. <i>HemaSphere</i> , 2020, 4, e452.	2.7	5
50	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <i>Blood Advances</i> , 2020, 4, 4267-4277.	5.2	14
51	Clonal Hematopoiesis in Hospitalized Elderly Patients With COVID-19. <i>HemaSphere</i> , 2020, 4, e453.	2.7	23
52	A Single Metabolite which Modulates Lipid Metabolism Alters Hematopoietic Stem/Progenitor Cell Behavior and Promotes Lymphoid Reconstitution. <i>Stem Cell Reports</i> , 2020, 15, 566-576.	4.8	10
53	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2020, 135, 1548-1559.	1.4	58
54	Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. <i>Leukemia</i> , 2020, 34, 2688-2703.	7.2	52

#	ARTICLE	IF	CITATIONS
55	Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2533-2535.	1.3	0
56	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. <i>Blood Advances</i> , 2020, 4, 2477-2488.	5.2	15
57	Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing. <i>Bioconjugate Chemistry</i> , 2020, 31, 1775-1783.	3.6	12
58	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. <i>Nature Medicine</i> , 2020, 26, 1459-1467.	30.7	122
59	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1751-1759.	7.2	18
60	EBV renders B cells susceptible to HIV-1 in humanized mice. <i>Life Science Alliance</i> , 2020, 3, e202000640.	2.8	22
61	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 685-695.	1.3	1
62	Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 84, 106178.	0.8	17
63	Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. <i>Nature Communications</i> , 2019, 10, 4986.	12.8	24
64	THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 127-127.	1.7	0
65	The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. <i>EMBO Molecular Medicine</i> , 2019, 11, e10576.	6.9	38
66	Fate Distribution and Regulatory Role of Human Mesenchymal Stromal Cells in Engineered Hematopoietic Bone Organs. <i>IScience</i> , 2019, 19, 504-513.	4.1	13
67	A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. <i>Nature Communications</i> , 2019, 10, 366.	12.8	60
68	Selective CD117+ HSC exchange therapy. <i>Blood</i> , 2019, 133, 2007-2009.	1.4	3
69	Sensitive Quantitative Proteomics of Human Hematopoietic Stem and Progenitor Cells by Data-independent Acquisition Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1454-1467.	3.8	43
70	Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3020-3032.	5.2	19
71	Global Transcriptomic Profiling of the Bone Marrow Stromal Microenvironment during Postnatal Development, Aging, and Inflammation. <i>Cell Reports</i> , 2019, 29, 3313-3330.e4.	6.4	79
72	The sympathomimetic agonist mirabegron did not lower <i>JAK2</i> -V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. <i>Haematologica</i> , 2019, 104, 710-716.	3.5	29

#	ARTICLE	IF	CITATIONS
73	CD34+CD38 ^{hi} leukemic stem cell frequency to predict outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1102-1112.	7.2	130
74	Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans. <i>Blood</i> , 2019, 134, 234-234.	1.4	8
75	Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia. <i>Hematological Oncology</i> , 2018, 36, 471-480.	1.7	5
76	The tumor suppressive TGF- β 2/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2235-2246.	1.4	41
77	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. <i>Cancer</i> , 2018, 124, 2607-2620.	4.1	73
78	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. <i>Bioinformatics</i> , 2018, 34, 107-108.	4.1	25
79	Engineered humanized bone organs maintain human hematopoiesis in vivo. <i>Experimental Hematology</i> , 2018, 61, 45-51.e5.	0.4	17
80	Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 694-699.	2.0	5
81	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1189-1199.	27.0	605
82	Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving L-asparaginase. <i>Leukemia and Lymphoma</i> , 2018, 59, 855-862.	1.3	9
83	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , 2018, 283, 371-379.	6.0	19
84	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. <i>Cancer Epidemiology</i> , 2018, 52, 55-62.	1.9	8
85	R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. <i>Annals of Hematology</i> , 2018, 97, 277-287.	1.8	11
86	Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	68
87	A novel dual-cytokine antibody fusion protein for the treatment of CD38-positive malignancies. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 173-179.	2.1	9
88	Quantitative spatial analysis of haematopoiesis-regulating stromal cells in the bone marrow microenvironment by 3D microscopy. <i>Nature Communications</i> , 2018, 9, 2532.	12.8	109
89	Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency—a case report and comprehensive review of the literature. <i>Annals of Hematology</i> , 2018, 97, 1961-1973.	1.8	24
90	Finally: development of humanized lymph nodes. <i>Nature Methods</i> , 2018, 15, 580-582.	19.0	2

#	ARTICLE	IF	CITATIONS
91	Plasmacytoid dendritic cells: origin matters. <i>Nature Immunology</i> , 2018, 19, 652-654.	14.5	11
92	Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial. <i>Blood</i> , 2018, 132, 2680-2680.	1.4	16
93	Graft-Vs-Host Reactivity Against the Bone Marrow Is Directed Against the Hematopoietic and Non-Hematopoietic Compartments in Mice. <i>Blood</i> , 2018, 132, 808-808.	1.4	0
94	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. <i>Blood</i> , 2017, 129, 1636-1645.	1.4	77
95	Regulation of Inflammation- and Infection-Driven Hematopoiesis. <i>Trends in Immunology</i> , 2017, 38, 345-357.	6.8	209
96	sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon- α therapy. <i>Annals of Hematology</i> , 2017, 96, 757-763.	1.8	1
97	Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and <i>CEP110</i> - <i>FCFR1</i> Rearrangement. <i>Oncologist</i> , 2017, 22, 480-483.	3.7	10
98	A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. <i>Blood</i> , 2017, 129, 959-969.	1.4	105
99	Impact of inflammation on early hematopoiesis and the microenvironment. <i>International Journal of Hematology</i> , 2017, 106, 27-33.	1.6	35
100	Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 9701-9706.	7.1	97
101	Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness. <i>Cell Stem Cell</i> , 2017, 21, 225-240.e5.	11.1	210
102	Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2017, 58, 1068-1075.	1.3	20
103	NLRP3 Controls the Development of Gastrointestinal CD11b + Dendritic Cells in the Steady State and during Chronic Bacterial Infection. <i>Cell Reports</i> , 2017, 21, 3860-3872.	6.4	52
104	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.0	14
105	Quantification and three-dimensional microanatomical organization of the bone marrow. <i>Blood Advances</i> , 2017, 1, 407-416.	5.2	84
106	Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments. <i>PLoS Computational Biology</i> , 2017, 13, e1005803.	3.2	26
107	Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013. <i>Blood</i> , 2017, 130, 863-863.	1.4	0
108	Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy. <i>Case Reports in Hematology</i> , 2016, 2016, 1-5.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 502.	4.8	272
110	Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies. <i>Transfusion</i> , 2016, 56, 2426-2437.	1.6	26
111	Sensing and translation of pathogen signals into demand-adapted myelopoiesis. <i>Current Opinion in Hematology</i> , 2016, 23, 5-10.	2.5	50
112	inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. <i>Blood</i> , 2016, 128, 2130-2134.	1.4	40
113	Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice. <i>Blood</i> , 2016, 128, 1829-1833.	1.4	80
114	Generation of Humanized Mice for Analysis of Human Dendritic Cells. <i>Methods in Molecular Biology</i> , 2016, 1423, 309-320.	0.9	12
115	Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. <i>Nature Cell Biology</i> , 2016, 18, 607-618.	10.3	519
116	Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. <i>Blood</i> , 2016, 127, 3253-3259.	1.4	37
117	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. <i>Nature Medicine</i> , 2016, 22, 1351-1357.	30.7	132
118	Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. <i>Blood</i> , 2016, 127, 3175-3179.	1.4	44
119	Inflammatory signals in HSPC development and homeostasis: Too much of a good thing?. <i>Experimental Hematology</i> , 2016, 44, 908-912.	0.4	14
120	MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. <i>Blood</i> , 2016, 128, 2253-2257.	1.4	34
121	Humanized hemato-lymphoid system mice. <i>Haematologica</i> , 2016, 101, 5-19.	3.5	166
122	Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. <i>Blood</i> , 2016, 128, 3108-3108.	1.4	4
123	The Bone Marrow Microenvironment Is a Target of Graft-Vs-Host Reactivity Following Allogeneic Hematopoietic Cell Transplantation in Mice. <i>Blood</i> , 2016, 128, 4539-4539.	1.4	0
124	CXCL12-Abundant Reticular (CAR) Cells Are Key Regulators for a Sustained Hematopoietic Response during Chronic Inflammation. <i>Blood</i> , 2016, 128, 429-429.	1.4	0
125	BRAFV600E Transduced Human CD34+ Cells Establish Aggressive Langerhans Cell Histiocytosis in Humanized Mice. <i>Blood</i> , 2016, 128, 2739-2739.	1.4	0
126	Inv(16) AML Engrafts Human Cytokine Knock-in Mice. <i>Blood</i> , 2016, 128, 1078-1078.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. <i>Journal of Virology</i> , 2015, 89, 6761-6772.	3.4	30
128	Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 811-815.	0.4	5
129	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. <i>Blood</i> , 2015, 126, 120-120.	1.4	1
130	Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal. <i>Blood</i> , 2015, 126, 778-778.	1.4	0
131	Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells. <i>Blood</i> , 2015, 126, 22-22.	1.4	3
132	Mpl Expression on AML Blasts Predicts Cytopenia. <i>Blood</i> , 2015, 126, 1387-1387.	1.4	0
133	DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. <i>Nature Cell Biology</i> , 2014, 16, 812-820.	10.3	39
134	A novel mouse model for inhibition of DOHH mediated hypusine modification reveals crucial function for embryonic development, proliferation and oncogenic transformation. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 963-76.	2.4	46
135	Development and function of human innate immune cells in a humanized mouse model. <i>Nature Biotechnology</i> , 2014, 32, 364-372.	17.5	629
136	Emergency granulopoiesis. <i>Nature Reviews Immunology</i> , 2014, 14, 302-314.	22.7	625
137	<i>BRAF</i> -V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. <i>Journal of Experimental Medicine</i> , 2014, 211, 669-683.	8.5	346
138	Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis. <i>Blood</i> , 2014, 124, 1393-1403.	1.4	221
139	Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing <i>JAK2</i> -V617F. <i>Journal of Experimental Medicine</i> , 2014, 211, 2213-2230.	8.5	88
140	Microbiota-Derived Compounds Drive Steady-State Granulopoiesis via MyD88/TICAM Signaling. <i>Journal of Immunology</i> , 2014, 193, 5273-5283.	0.8	202
141	Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. <i>Experimental Hematology and Oncology</i> , 2014, 3, 18.	5.0	5
142	A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development. <i>Journal of Proteomics</i> , 2014, 99, 138-151.	2.4	24
143	Î© TM SÎRG Mice Support Good-Risk AML Engraftment. <i>Blood</i> , 2014, 124, 3808-3808.	1.4	1
144	Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: A real-world, retrospective comparative single-centre study. <i>Swiss Medical Weekly</i> , 2014, 144, w13985.	1.6	8

#	ARTICLE	IF	CITATIONS
145	Next Generation Humanized Mice Support Engraftment of Myelofibrosis CD34+ Cells. <i>Blood</i> , 2014, 124, 1880-1880.	1.4	4
146	Direct Sensing of Lipopolysaccharide Limits Hematopoietic Stem Cell Selfrenewal Via TLR4-TRIF-ROS-p38 Pathway. <i>Blood</i> , 2014, 124, 604-604.	1.4	0
147	Adult Donor-Derived Human CD34+ Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice. <i>Blood</i> , 2014, 124, 4378-4378.	1.4	0
148	Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine. <i>Annual Review of Immunology</i> , 2013, 31, 635-674.	21.8	304
149	Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice. <i>PLoS Pathogens</i> , 2013, 9, e1003587.	4.7	55
150	Engineering of a functional bone organ through endochondral ossification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3997-4002.	7.1	289
151	Dendritic cell homeostasis is maintained by nonhematopoietic and α cell-produced β ligand in steady state and during immune responses. <i>European Journal of Immunology</i> , 2013, 43, 1651-1658.	2.9	31
152	Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRP α -Transgenic-Human-TPO-Expressing RAG2 $^{-/-}$, IL2R β $^{-/-}$ Immunodeficient Mice. <i>Blood</i> , 2013, 122, 2844-2844.	1.4	0
153	Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia. <i>Blood</i> , 2013, 122, 103-103.	1.4	0
154	<i>In vivo</i> divisional tracking of hematopoietic stem cells. <i>Annals of the New York Academy of Sciences</i> , 2012, 1266, 40-46.	3.8	5
155	Demand-adapted regulation of early hematopoiesis in infection and inflammation. <i>Blood</i> , 2012, 119, 2991-3002.	1.4	351
156	Lymphotoxin β Receptor Signaling Promotes Development of Autoimmune Pancreatitis. <i>Gastroenterology</i> , 2012, 143, 1361-1374.	1.3	45
157	Cutting Edge: LPS-Induced Emergency Myelopoiesis Depends on TLR4-Expressing Nonhematopoietic Cells. <i>Journal of Immunology</i> , 2012, 188, 5824-5828.	0.8	129
158	Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2390-2395.	7.1	202
159	Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2378-2383.	7.1	169
160	Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. <i>Trends in Immunology</i> , 2011, 32, 321-327.	6.8	117
161	Efficient differentiation and function of human macrophages in humanized CSF-1 mice. <i>Blood</i> , 2011, 118, 3119-3128.	1.4	134
162	Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes. <i>Blood</i> , 2011, 118, 4829-4840.	1.4	62

#	ARTICLE	IF	CITATIONS
163	Dynamic regulation of hematopoietic stem cell cycling. <i>Cell Cycle</i> , 2011, 10, 2246-2247.	2.6	1
164	Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. <i>Journal of Experimental Medicine</i> , 2011, 208, 273-284.	8.5	271
165	Transgenic expression of human signal regulatory protein alpha in Rag2 ^{Δα} β ^c mice improves engraftment of human hematopoietic cells in humanized mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13218-13223.	7.1	205
166	HTLV-1 Propels Thymic Human T Cell Development in α Human Immune System β •Rag2 ⁻ gamma c ⁻ Mice. <i>PLoS Pathogens</i> , 2011, 7, e1002231.	4.7	61
167	JAK2-V617F Expressing Stem Cells Display a Competitive Advantage At Low Limiting Dilution and Are Capable of Initiating MPN Phenotype. <i>Blood</i> , 2011, 118, 615-615.	1.4	1
168	Allogeneic Transplantation for Multiple Myeloma α the Swiss Experience. <i>Blood</i> , 2011, 118, 3112-3112.	1.4	0
169	Development of Monocytes, Macrophages, and Dendritic Cells. <i>Science</i> , 2010, 327, 656-661.	12.6	2,471
170	Non-Hematopoietic Stromal Cells Sense Toll-Like Receptor 4 Agonists and Consequently Enhance Myelopoiesis.. <i>Blood</i> , 2010, 116, 2583-2583.	1.4	0
171	Renaissance for mouse models of human hematopoiesis and immunobiology. <i>Nature Immunology</i> , 2009, 10, 1039-1042.	14.5	81
172	Dendritic cell homeostasis. <i>Blood</i> , 2009, 113, 3418-3427.	1.4	332
173	The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. <i>Blood</i> , 2009, 114, 835-843.	1.4	200
174	Human-Hemato-Lymphoid-System Mice: Opportunities and Challenges. <i>Immunity</i> , 2007, 26, 537-541.	14.3	206
175	Macrophage tolerance: CD47 α SIRP β mediated signals matter. <i>Nature Immunology</i> , 2007, 8, 1287-1289.	14.5	56
176	Identification of clonogenic common Flt3 ⁺ M-CSFR ⁺ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. <i>Nature Immunology</i> , 2007, 8, 1207-1216.	14.5	628
177	Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon α producing and dendritic cell development. <i>Journal of Experimental Medicine</i> , 2006, 203, 227-238.	8.5	146
178	Disseminated and sustained HIV infection in CD34 ⁺ cord blood cell-transplanted Rag2 ⁻ β ⁻ mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15951-15956.	7.1	224
179	Inhibition of Natural Type I IFN-Producing and Dendritic Cell Development by a Small Molecule Receptor Tyrosine Kinase Inhibitor with Flt3 Affinity. <i>Journal of Immunology</i> , 2005, 175, 3674-3680.	0.8	56
180	Clonal Type I Interferon α producing and Dendritic Cell Precursors Are Contained in Both Human Lymphoid and Myeloid Progenitor Populations. <i>Journal of Experimental Medicine</i> , 2004, 200, 1519-1524.	8.5	103

#	ARTICLE	IF	CITATIONS
181	Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice. <i>Science</i> , 2004, 304, 104-107.	12.6	934
182	Flt3 Ligand Regulates Dendritic Cell Development from Flt3+ Lymphoid and Myeloid-committed Progenitors to Flt3+ Dendritic Cells In Vivo. <i>Journal of Experimental Medicine</i> , 2003, 198, 305-313.	8.5	513
183	BIOLOGY OFHEMATOPOIETICSTEMCELLS ANDPROGENITORS: Implications for Clinical Application. <i>Annual Review of Immunology</i> , 2003, 21, 759-806.	21.8	888
184	Prospective isolation of human clonogenic common myeloid progenitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11872-11877.	7.1	460
185	Plasmacytoid dendritic cells: ready to be tested in vivo. <i>Blood</i> , 2001, 98, 3503-3503.	1.4	0
186	Dendritic cell potentials of early lymphoid and myeloid progenitors. <i>Blood</i> , 2001, 97, 3333-3341.	1.4	357
187	Development of CD8 α^+ -Positive Dendritic Cells from a Common Myeloid Progenitor. <i>Science</i> , 2000, 290, 2152-2154.	12.6	363
188	Romiplostim addition to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels. <i>Blood Advances</i> , 0, , .	5.2	0